INC Research spells out details on $150M IPO

INC Research has spelled out its IPO plans, looking to raise $150 million through the sale of 8.1 million shares at $17 to $20 a share. Renaissance Capital reports that at the midpoint of that range, INC would be left with a market cap of $1.1 billion. A number of CROs have been going public this year as improved sentiment for biotech has kept the IPO window in the industry open for two years now. INC will be hoping that investors look past some turbulence in the market to embrace the company. Story

Suggested Articles

The project is built on the AlivaMab Mouse platform that is already widely used by in-house R&D teams at large biopharma companies.

The takeover centers on a near-approval anti-CGRP antibody that could address Lundbeck’s need for near-term revenue drivers.

As the White House continues its push for the benefits of "right to try," the first CRO associated with the law has come onto the stage.